Flagship-backed cancer biotech Ensemble quietly shuts down
During its 13-year existence, the Cambridge biotech made waves by announcing a series of partnership deals with large drugmakers. But it raised relatively little in equity financing and never launched a clinical trial.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Max Stendahl Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Health Management | Partnerships